Is the UK about to stop getting new drugs?
Not because the science is slowing down.
Because pricing is getting weaponised.
Most Favoured Nation pricing started as a US problem. It is now a global market access problem, and the UK is right in the blast radius.
MFN, in plain English, means the US wants “the price paid in other comparable countries”, and it wants manufacturers to get there. The May 12 2025, US Executive Order explicitly sets that direction, with HHS and CMS told to communicate MFN price targets to manufacturers.
Here is the bit UK teams cannot ignore. The moment the US starts looking outward for pricing benchmarks, every “good UK deal” becomes a potential US liability. That changes behaviour, fast.
And we have evidence that this is not just a theory.
A UK-US pricing shockwave is already here
On 1 December 2025, the US government announced an “agreement in principle” with the UK on pharmaceutical pricing. Buried in the detail, the UK commits that higher prices for new medicines should not be materially eroded by portfolio-wide concessions under VPAG or other rebate schemes, and that the VPAG repayment rate will drop to 15% in 2026 and stay at or below that level.
That is not a small tweak; it is a directional signal.
Then, in February 2026, UK reporting put hard numbers on what this could mean for the NHS, with concerns that the deal implies paying 25% higher prices for new drugs, funded from within DHSC budgets, with longer-term costs potentially rising sharply by 2035.
Whether you agree with the framing or not, the market signal is obvious: the UK is being pulled into a US pricing agenda.
Now look at what is happening on the NICE side.
NICE appraisal friction is rising, and it is visible in the data
There has been a headline doing the rounds that suspended NICE technology appraisals are up 50%. You can debate the exact baseline and definitions, but the direction is hard to argue with.
NICE’s own Resource Planner shows a big block of technology appraisals sitting in “Suspended” status. In the latest edition published 6 February 2026, the Technology Appraisals sheet contains 84 appraisals marked as suspended.
When you compare snapshots, you can see the drift. The August 2025 “final” resource planner shows 72 suspended technology appraisals. The February 2026 edition shows 84, a clear rise over a short period.
Terminations are also climbing. The August 2025 edition shows 26 terminated appraisals, the February 2026 edition shows 36.
What is driving suspensions? NICE’s own notes often cite very practical manufacturer decisions, for example, not pursuing MHRA authorisation “at this time” or not providing an evidence submission, which is exactly what you would expect to see when launch sequencing, price protection, or global filing priorities start tightening up.
ABPI has also flagged this as a real issue, pointing to an emerging trend of increased NICE terminations and discontinued topics.
So, is MFN the only cause? No. But if you are asking whether MFN is influencing market access thinking, the answer is yes, because it increases price spillover risk, and it changes what “safe to discount in the UK” means.
The consensus I am seeing, and it is getting stronger
Most teams I speak to are not saying, MFN will definitely be implemented perfectly, therefore we must panic.
They are saying that the uncertainty is enough to change behaviour now.
Three things are becoming the default assumptions:
The UK can no longer be treated as a low-risk early launch market if US pricing is in play.
Confidential discounts stop feeling “confidential” when the world is looking for reference points, even if technically it is the list price that gets referenced, perception drives decisions.
Launch sequencing will get more conservative, especially for high-budget impact therapies where a deep UK deal could ripple.
That aligns with wider evidence on international reference pricing style policies. A systematic review on external reference pricing found that low prices can undermine availability and lead to launch delays, launch sequencing, or even product withdrawals.
And legal and policy commentary is explicit that MFN policies can create upward pressure on other countries’ prices, not just downward pressure on US prices, because manufacturers and governments react strategically.
Now, the bit everyone actually cares about.
If MFN forces UK-US pricing equalisation, what are the UK scenarios?
There are a few credible paths, and none are comfortable.
The UK pays more, access stays, but the system tightens elsewhere
Patients might still get the drug, but later, narrower, and with harder implementation hurdles.
The UK holds the line, manufacturers hold the launch
This shows up as more suspended appraisals, more terminated topics, and more “UK is wave 2 or wave 3” launch strategy.
List price inflation, discounts go dark, complexity goes up
Good luck explaining that to global without a long meeting and a big spreadsheet.
Policy redesign, the UK tries to buy its way back into the “first wave”
You can see early signals of this direction in the policy and trade discussions around VPAG and how “higher prices for new medicines” are being protected from broad rebate erosion.
Worst case, the UK becomes a no-launch market for some products
But for certain high-cost, high-sensitivity assets, the UK could become the market where companies decide the risk is not worth it, at least until the US price is locked and global corridors are set.
That is how you end up with patients reading about approvals elsewhere while the UK waits for “commercial alignment”.
So here is the uncomfortable question
If we keep stacking MFN risk on top of UK affordability pressure, and we keep seeing NICE topics suspended or terminated, are we heading for a world where the UK simply stops getting a meaningful share of new launches, at least on time?
If you are in Market Access, Pricing, HEOR, or Commercial, how is MFN changing your UK plans right now? Are you changing sequencing, holding price, reshaping discount strategy, or rethinking whether you even go to NICE in the same way?